PMC:7105881 / 35358-36315 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1121","span":{"begin":670,"end":673},"obj":"Gene"},{"id":"1122","span":{"begin":348,"end":352},"obj":"Species"},{"id":"1123","span":{"begin":371,"end":379},"obj":"Species"},{"id":"1124","span":{"begin":466,"end":474},"obj":"Species"},{"id":"1125","span":{"begin":560,"end":564},"obj":"Species"},{"id":"1126","span":{"begin":685,"end":693},"obj":"Species"},{"id":"1127","span":{"begin":757,"end":765},"obj":"Species"},{"id":"1128","span":{"begin":214,"end":225},"obj":"Species"},{"id":"1129","span":{"begin":454,"end":465},"obj":"Species"},{"id":"1130","span":{"begin":912,"end":920},"obj":"Species"},{"id":"1131","span":{"begin":145,"end":163},"obj":"Disease"}],"attributes":[{"id":"A1121","pred":"tao:has_database_id","subj":"1121","obj":"Gene:67414"},{"id":"A1122","pred":"tao:has_database_id","subj":"1122","obj":"Tax:10090"},{"id":"A1123","pred":"tao:has_database_id","subj":"1123","obj":"Tax:694009"},{"id":"A1124","pred":"tao:has_database_id","subj":"1124","obj":"Tax:694009"},{"id":"A1125","pred":"tao:has_database_id","subj":"1125","obj":"Tax:10090"},{"id":"A1126","pred":"tao:has_database_id","subj":"1126","obj":"Tax:694009"},{"id":"A1127","pred":"tao:has_database_id","subj":"1127","obj":"Tax:694009"},{"id":"A1128","pred":"tao:has_database_id","subj":"1128","obj":"Tax:575864"},{"id":"A1129","pred":"tao:has_database_id","subj":"1129","obj":"Tax:575864"},{"id":"A1130","pred":"tao:has_database_id","subj":"1130","obj":"Tax:694009"},{"id":"A1131","pred":"tao:has_database_id","subj":"1131","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"SARS subunit vaccines based on S protein fragments (S1 and S2), other than the RBD, have shown immunogenicity and/or protective efficacy against SARS-CoV infection (Guo et al., 2005; Li et al., 2013). For example, recombinant S1 proteins fused with or without foldon elicited specific antibodies with neutralizing activity that protected immunized mice against high-dose SARS-CoV challenge (Li et al., 2013). Although some studies have demonstrated that recombinant SARS-CoV S2 (residues 681–980) protein elicits specific non-neutralizing antibody response in mice (Guo et al., 2005), others have indicated that mAbs targeting highly conserved heptad repeat 1 (HR1) and HR2 domains of SARS-CoV S protein have broad neutralizing activity against pseudotyped SARS-CoV expressing S protein of divergent strains (Elshabrawy et al., 2012), indicating the potential of utilizing the S2 region as a broad-spectrum anti-SARS-CoV vaccine target (Zheng et al., 2009)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T201","span":{"begin":33,"end":40},"obj":"Body_part"},{"id":"T202","span":{"begin":229,"end":237},"obj":"Body_part"},{"id":"T203","span":{"begin":497,"end":504},"obj":"Body_part"},{"id":"T204","span":{"begin":539,"end":547},"obj":"Body_part"},{"id":"T205","span":{"begin":696,"end":703},"obj":"Body_part"},{"id":"T206","span":{"begin":779,"end":786},"obj":"Body_part"}],"attributes":[{"id":"A201","pred":"fma_id","subj":"T201","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A202","pred":"fma_id","subj":"T202","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A203","pred":"fma_id","subj":"T203","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A204","pred":"fma_id","subj":"T204","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A205","pred":"fma_id","subj":"T205","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A206","pred":"fma_id","subj":"T206","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"SARS subunit vaccines based on S protein fragments (S1 and S2), other than the RBD, have shown immunogenicity and/or protective efficacy against SARS-CoV infection (Guo et al., 2005; Li et al., 2013). For example, recombinant S1 proteins fused with or without foldon elicited specific antibodies with neutralizing activity that protected immunized mice against high-dose SARS-CoV challenge (Li et al., 2013). Although some studies have demonstrated that recombinant SARS-CoV S2 (residues 681–980) protein elicits specific non-neutralizing antibody response in mice (Guo et al., 2005), others have indicated that mAbs targeting highly conserved heptad repeat 1 (HR1) and HR2 domains of SARS-CoV S protein have broad neutralizing activity against pseudotyped SARS-CoV expressing S protein of divergent strains (Elshabrawy et al., 2012), indicating the potential of utilizing the S2 region as a broad-spectrum anti-SARS-CoV vaccine target (Zheng et al., 2009)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T194","span":{"begin":0,"end":4},"obj":"Disease"},{"id":"T195","span":{"begin":145,"end":163},"obj":"Disease"},{"id":"T196","span":{"begin":154,"end":163},"obj":"Disease"},{"id":"T197","span":{"begin":371,"end":379},"obj":"Disease"},{"id":"T198","span":{"begin":466,"end":474},"obj":"Disease"},{"id":"T199","span":{"begin":685,"end":693},"obj":"Disease"},{"id":"T200","span":{"begin":757,"end":765},"obj":"Disease"},{"id":"T201","span":{"begin":912,"end":920},"obj":"Disease"}],"attributes":[{"id":"A194","pred":"mondo_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A195","pred":"mondo_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A196","pred":"mondo_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A197","pred":"mondo_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A198","pred":"mondo_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A199","pred":"mondo_id","subj":"T199","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A200","pred":"mondo_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A201","pred":"mondo_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"SARS subunit vaccines based on S protein fragments (S1 and S2), other than the RBD, have shown immunogenicity and/or protective efficacy against SARS-CoV infection (Guo et al., 2005; Li et al., 2013). For example, recombinant S1 proteins fused with or without foldon elicited specific antibodies with neutralizing activity that protected immunized mice against high-dose SARS-CoV challenge (Li et al., 2013). Although some studies have demonstrated that recombinant SARS-CoV S2 (residues 681–980) protein elicits specific non-neutralizing antibody response in mice (Guo et al., 2005), others have indicated that mAbs targeting highly conserved heptad repeat 1 (HR1) and HR2 domains of SARS-CoV S protein have broad neutralizing activity against pseudotyped SARS-CoV expressing S protein of divergent strains (Elshabrawy et al., 2012), indicating the potential of utilizing the S2 region as a broad-spectrum anti-SARS-CoV vaccine target (Zheng et al., 2009)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T461","span":{"begin":52,"end":54},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T462","span":{"begin":59,"end":61},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T463","span":{"begin":59,"end":61},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"},{"id":"T464","span":{"begin":183,"end":185},"obj":"http://purl.obolibrary.org/obo/CLO_0001022"},{"id":"T465","span":{"begin":183,"end":185},"obj":"http://purl.obolibrary.org/obo/CLO_0007314"},{"id":"T466","span":{"begin":226,"end":228},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T467","span":{"begin":314,"end":322},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T468","span":{"begin":391,"end":393},"obj":"http://purl.obolibrary.org/obo/CLO_0001022"},{"id":"T469","span":{"begin":391,"end":393},"obj":"http://purl.obolibrary.org/obo/CLO_0007314"},{"id":"T470","span":{"begin":475,"end":477},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T471","span":{"begin":475,"end":477},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"},{"id":"T472","span":{"begin":728,"end":736},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T473","span":{"begin":877,"end":879},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T474","span":{"begin":877,"end":879},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"},{"id":"T475","span":{"begin":890,"end":891},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"SARS subunit vaccines based on S protein fragments (S1 and S2), other than the RBD, have shown immunogenicity and/or protective efficacy against SARS-CoV infection (Guo et al., 2005; Li et al., 2013). For example, recombinant S1 proteins fused with or without foldon elicited specific antibodies with neutralizing activity that protected immunized mice against high-dose SARS-CoV challenge (Li et al., 2013). Although some studies have demonstrated that recombinant SARS-CoV S2 (residues 681–980) protein elicits specific non-neutralizing antibody response in mice (Guo et al., 2005), others have indicated that mAbs targeting highly conserved heptad repeat 1 (HR1) and HR2 domains of SARS-CoV S protein have broad neutralizing activity against pseudotyped SARS-CoV expressing S protein of divergent strains (Elshabrawy et al., 2012), indicating the potential of utilizing the S2 region as a broad-spectrum anti-SARS-CoV vaccine target (Zheng et al., 2009)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T204","span":{"begin":33,"end":40},"obj":"Chemical"},{"id":"T205","span":{"begin":59,"end":61},"obj":"Chemical"},{"id":"T206","span":{"begin":165,"end":168},"obj":"Chemical"},{"id":"T207","span":{"begin":183,"end":185},"obj":"Chemical"},{"id":"T208","span":{"begin":229,"end":237},"obj":"Chemical"},{"id":"T209","span":{"begin":391,"end":393},"obj":"Chemical"},{"id":"T210","span":{"begin":475,"end":477},"obj":"Chemical"},{"id":"T211","span":{"begin":497,"end":504},"obj":"Chemical"},{"id":"T212","span":{"begin":566,"end":569},"obj":"Chemical"},{"id":"T213","span":{"begin":696,"end":703},"obj":"Chemical"},{"id":"T214","span":{"begin":779,"end":786},"obj":"Chemical"},{"id":"T215","span":{"begin":877,"end":879},"obj":"Chemical"}],"attributes":[{"id":"A204","pred":"chebi_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A205","pred":"chebi_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"},{"id":"A206","pred":"chebi_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/CHEBI_16750"},{"id":"A207","pred":"chebi_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/CHEBI_30145"},{"id":"A208","pred":"chebi_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A209","pred":"chebi_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/CHEBI_30145"},{"id":"A210","pred":"chebi_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"},{"id":"A211","pred":"chebi_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A212","pred":"chebi_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/CHEBI_16750"},{"id":"A213","pred":"chebi_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A214","pred":"chebi_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A215","pred":"chebi_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"}],"text":"SARS subunit vaccines based on S protein fragments (S1 and S2), other than the RBD, have shown immunogenicity and/or protective efficacy against SARS-CoV infection (Guo et al., 2005; Li et al., 2013). For example, recombinant S1 proteins fused with or without foldon elicited specific antibodies with neutralizing activity that protected immunized mice against high-dose SARS-CoV challenge (Li et al., 2013). Although some studies have demonstrated that recombinant SARS-CoV S2 (residues 681–980) protein elicits specific non-neutralizing antibody response in mice (Guo et al., 2005), others have indicated that mAbs targeting highly conserved heptad repeat 1 (HR1) and HR2 domains of SARS-CoV S protein have broad neutralizing activity against pseudotyped SARS-CoV expressing S protein of divergent strains (Elshabrawy et al., 2012), indicating the potential of utilizing the S2 region as a broad-spectrum anti-SARS-CoV vaccine target (Zheng et al., 2009)."}

{"project":"2_test","denotations":[{"id":"32265848-16101349-36511148","span":{"begin":177,"end":181},"obj":"16101349"},{"id":"32265848-23573979-36511149","span":{"begin":194,"end":198},"obj":"23573979"},{"id":"32265848-23573979-36511150","span":{"begin":402,"end":406},"obj":"23573979"},{"id":"32265848-16101349-36511151","span":{"begin":578,"end":582},"obj":"16101349"},{"id":"32265848-23185609-36511152","span":{"begin":828,"end":832},"obj":"23185609"},{"id":"32265848-19523911-36511153","span":{"begin":951,"end":955},"obj":"19523911"}],"text":"SARS subunit vaccines based on S protein fragments (S1 and S2), other than the RBD, have shown immunogenicity and/or protective efficacy against SARS-CoV infection (Guo et al., 2005; Li et al., 2013). For example, recombinant S1 proteins fused with or without foldon elicited specific antibodies with neutralizing activity that protected immunized mice against high-dose SARS-CoV challenge (Li et al., 2013). Although some studies have demonstrated that recombinant SARS-CoV S2 (residues 681–980) protein elicits specific non-neutralizing antibody response in mice (Guo et al., 2005), others have indicated that mAbs targeting highly conserved heptad repeat 1 (HR1) and HR2 domains of SARS-CoV S protein have broad neutralizing activity against pseudotyped SARS-CoV expressing S protein of divergent strains (Elshabrawy et al., 2012), indicating the potential of utilizing the S2 region as a broad-spectrum anti-SARS-CoV vaccine target (Zheng et al., 2009)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T208","span":{"begin":0,"end":200},"obj":"Sentence"},{"id":"T209","span":{"begin":201,"end":408},"obj":"Sentence"},{"id":"T210","span":{"begin":409,"end":957},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SARS subunit vaccines based on S protein fragments (S1 and S2), other than the RBD, have shown immunogenicity and/or protective efficacy against SARS-CoV infection (Guo et al., 2005; Li et al., 2013). For example, recombinant S1 proteins fused with or without foldon elicited specific antibodies with neutralizing activity that protected immunized mice against high-dose SARS-CoV challenge (Li et al., 2013). Although some studies have demonstrated that recombinant SARS-CoV S2 (residues 681–980) protein elicits specific non-neutralizing antibody response in mice (Guo et al., 2005), others have indicated that mAbs targeting highly conserved heptad repeat 1 (HR1) and HR2 domains of SARS-CoV S protein have broad neutralizing activity against pseudotyped SARS-CoV expressing S protein of divergent strains (Elshabrawy et al., 2012), indicating the potential of utilizing the S2 region as a broad-spectrum anti-SARS-CoV vaccine target (Zheng et al., 2009)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T602","span":{"begin":0,"end":4},"obj":"SP_10"},{"id":"T603","span":{"begin":31,"end":40},"obj":"PG_1"},{"id":"T604","span":{"begin":95,"end":109},"obj":"BV_15"},{"id":"T605","span":{"begin":145,"end":153},"obj":"SP_10"},{"id":"T606","span":{"begin":285,"end":295},"obj":"GO:0042571"},{"id":"T607","span":{"begin":348,"end":352},"obj":"NCBITaxon:10088"},{"id":"T608","span":{"begin":371,"end":379},"obj":"SP_10"},{"id":"T609","span":{"begin":466,"end":474},"obj":"SP_10"},{"id":"T610","span":{"begin":539,"end":547},"obj":"GO:0042571;BV_1"},{"id":"T611","span":{"begin":548,"end":556},"obj":"BV_1"},{"id":"T612","span":{"begin":560,"end":564},"obj":"NCBITaxon:10088"},{"id":"T613","span":{"begin":674,"end":681},"obj":"SO:0000417"},{"id":"T614","span":{"begin":685,"end":693},"obj":"SP_10"},{"id":"T615","span":{"begin":694,"end":703},"obj":"PG_1"},{"id":"T616","span":{"begin":757,"end":765},"obj":"SP_10"},{"id":"T617","span":{"begin":766,"end":776},"obj":"GO:0010467"},{"id":"T618","span":{"begin":777,"end":786},"obj":"PG_1"},{"id":"T619","span":{"begin":912,"end":920},"obj":"SP_10"},{"id":"T74035","span":{"begin":0,"end":4},"obj":"SP_10"},{"id":"T1157","span":{"begin":31,"end":40},"obj":"PG_1"},{"id":"T76119","span":{"begin":95,"end":109},"obj":"BV_15"},{"id":"T86425","span":{"begin":145,"end":153},"obj":"SP_10"},{"id":"T21173","span":{"begin":285,"end":295},"obj":"GO:0042571"},{"id":"T4815","span":{"begin":348,"end":352},"obj":"NCBITaxon:10088"},{"id":"T43943","span":{"begin":371,"end":379},"obj":"SP_10"},{"id":"T86686","span":{"begin":466,"end":474},"obj":"SP_10"},{"id":"T51099","span":{"begin":539,"end":547},"obj":"GO:0042571;BV_1"},{"id":"T71867","span":{"begin":548,"end":556},"obj":"BV_1"},{"id":"T26244","span":{"begin":560,"end":564},"obj":"NCBITaxon:10088"},{"id":"T9990","span":{"begin":674,"end":681},"obj":"SO:0000417"},{"id":"T90369","span":{"begin":685,"end":693},"obj":"SP_10"},{"id":"T71807","span":{"begin":694,"end":703},"obj":"PG_1"},{"id":"T34495","span":{"begin":757,"end":765},"obj":"SP_10"},{"id":"T66894","span":{"begin":766,"end":776},"obj":"GO:0010467"},{"id":"T82161","span":{"begin":777,"end":786},"obj":"PG_1"},{"id":"T9081","span":{"begin":912,"end":920},"obj":"SP_10"}],"text":"SARS subunit vaccines based on S protein fragments (S1 and S2), other than the RBD, have shown immunogenicity and/or protective efficacy against SARS-CoV infection (Guo et al., 2005; Li et al., 2013). For example, recombinant S1 proteins fused with or without foldon elicited specific antibodies with neutralizing activity that protected immunized mice against high-dose SARS-CoV challenge (Li et al., 2013). Although some studies have demonstrated that recombinant SARS-CoV S2 (residues 681–980) protein elicits specific non-neutralizing antibody response in mice (Guo et al., 2005), others have indicated that mAbs targeting highly conserved heptad repeat 1 (HR1) and HR2 domains of SARS-CoV S protein have broad neutralizing activity against pseudotyped SARS-CoV expressing S protein of divergent strains (Elshabrawy et al., 2012), indicating the potential of utilizing the S2 region as a broad-spectrum anti-SARS-CoV vaccine target (Zheng et al., 2009)."}